Plain-English translation of NCT04836156 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new way to choose chemotherapy drugs for people with early breast cancer that is HER2-negative. Doctors will take a small sample of your tumor and grow cancer cells in the lab to see which chemotherapy drugs work best against your specific cancer. Based on those lab results, you'll receive personalized chemotherapy designed just for you.
Not all breast cancer patients benefit equally from the same chemotherapy drugs, and some people suffer serious side effects from treatments that won't help them. This trial exists to find a better way to match each patient with chemotherapy drugs that are most likely to work for their individual tumor, rather than using a one-size-fits-all approach.
You likely qualify if…
You likely don't qualify if…
You will have a small tumor sample taken and tested in the lab to determine which chemotherapy drugs are most effective for your cancer. Based on those results, you will then receive personalized neoadjuvant chemotherapy (chemotherapy given before surgery) that is tailored to your tumor's sensitivities. The study will follow your response to treatment to see if this personalized approach helps improve outcomes.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Peking University People's Hospital
Enrollment target
~46 participants
Started
April 2021
Primary completion
June 2022
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in April 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chaobin Wang, doctor
Peking University People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.